Clinical trial NCT02841085: New Genetic Mutations in Thromboembolic Venous Disease Idiopathic. Study "FIT GENETIQUE".
Official title: Search for New Mutations Genetic Predisposing to an Increased Risk Venous Thromboembolic Disease Idiopathic. Study "FIT GENETIQUE".
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Thromboembolic Venous Disease
Keywords: Genetic
Thrombophilia
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2016-07-22
Enrollment: 613
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: FAMILY_BASED
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Family members in the 1st, 2nd, 3rd and 4th degree (and their spouses if they have a descent) of patients (propositi) who:

1. / have a single episode of unprovoked venous thromboembolic disease without detectable inherited and acquired thrombophilia ;
2. / were included in the "FIT" study;
3. / consenting that their family members 2nd, 3rd and 4th degree are approached to participate in the this study.

Brief summary: Identify new genetic mutations predisposing to an increased risk of VTE by locating and / or identifying genes involved in subjects at high risk for thrombotic and in whom screening for detectable hereditary thrombophilia was negative.

Detailed description: Venous thromboembolism desease is a public health problem justifying major primary and secondary prevention policy. When VTE occurs in the absence of risk factor clinically identifiable ( "idiopathic"), an inherited biological risk factor ( "inherited thrombophilia") is found in 30% of cases. However, in patients with idiopathic VTE, the risk of recurrent venous thromboembolism is very high, whether detectable inherited thrombophilia was found or not.

This first observation suggests that patients with idiopathic VTE and no detectable thrombophilia are likely to have an underlying unknown thrombophilia that are yet to be discovered.

This hypothesis is further supported by the results of the study "FIT" (Regional PHRC 2001, promoter CHU Brest, Investigator Main: Francis Couturaud, EA3878 Brest, France, and investigator Associate: Clive Kearon, McMaster University, Hamilton, Ontario, Canada), a cross international study evaluating the risk of VTE among the family members first degree of patients a first idiopathic VTE episode. In this large study cross-1950 family members first degree (topics study) of 372 patients with a first episode of VTE Idiopathic (propositi) were included (50% included in Brest and 50% inclusive in Canada). The main result is that the risk of VTE among family members first degree is high and similar, the proband either bearer or without a detectable hereditary thrombophilia. In other words, even in the absence of detectable hereditary thrombophilia, the risk of VTE among family members first degree is high. This study has identified the subjects in that it is likely they have an inherited thrombophilia which has not yet been discovered.

Eligibility criteria: Inclusion Criteria:

* Family members in the 1st, 2nd, 3rd and 4th degree (and their spouses if they have a descent) of patients (propositi) who:

  1. / have a single episode of unprovoked venous thromboembolic disease without detectable inherited and acquired thrombophilia ;
  2. / were included in the "FIT" study;
  3. / consenting that their family members 2nd, 3rd and 4th degree are approached to participate in the this study.
* Written Consent of propositi and their members in the 2nd, 3rd and 4th respective degree to participate in this study.

Exclusion Criteria:

* Presence of detectable thrombophilia in the propositi.
* Presence of hereditary thrombophilia or detectable gained at family members.
* No information may be obtained on previous venous thromboembolism among family members on 1 degree
* Everything about the study (depending on the population and members of proband Family 1st, 2nd, 3rd and 4th degree) less than 15 years.
* The family member is an adopted child

Primary outcomes:
measure: Research of new genetic mutations
timeFrame: 1 day
Secondary outcomes:
measure: Quantify the presence of new thrombophilia hereditary risk of Thromboembolic Venous Disease
timeFrame: 1 day
Other outcomes:
Locations:
city: Brest
country: France
facility: CHRU de Brest
Study officials:
References: